retatrutide trial phase Eli Lilly's 3 clinical studies investigating retatrutide, the "triple-G" agonist, have found that long-term use can achieve substantial weight loss. Read about the work via the link in the comments Phase III retatrutide study demonstrates

COVERAGE STRATEGY If you have prediabetes or type 2 diabetes plus obesity, push your physician to prescribe for the diabetes indication rather than weight loss

If your provider recommends them, Medicare may cover B12 shots for you

There are no clinically relevant differences in medication exposure between approved injection sites, so you can choose based on comfort and accessibility

Schedule a Consultation at the Center for Weight Loss Surgery It can be challenging not to gain weight after stopping Ozempic, Wegogy, Mounjaro, Zepbound and other GLP-1s, but several alternatives can be more effective in the long term

One year